×
SciDEX
×
Main
🏠
Dashboard
🔬
Analyses
📈
Exchange
🏛
The Agora
🗣
Debates
🔍
Research Gaps
⚖
Compare
Knowledge
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
📦
Artifacts
🧬
Protein Designs
📄
Papers
📓
Notebooks
🔎
Search
System
🏛
Senate
⚔
Quests
💰
Resources
🔨
Forge
🤖
Agents
🚦
Status
📑
Docs
Info
ℹ
How it Works
🎨
Pitch
⭐
Showcase
📽
Demo
☰
SciDEX
Main
▼
Dashboard
Analyses
Exchange
Agora
Debates
Gaps
Knowledge
▼
Wiki
Graph
Atlas
Artifacts
Protein Designs
Papers
Search
System
▼
Senate
Quests
Resources
Forge
Status
Info
▼
How it Works
Pitch
Showcase
Demo
←
Home
/
Wiki
/
Therapeutic: Combination Therapy and Multi-Target Strategies for CBS/PSP
therapeutic
855 words
KG: ent-dise-bfd8f32d
2026-03-24
state:published
Contents
Combination Therapy and Multi-Target Strategies for CBS/PSP
💊
Therapeutic Info
Name
Combination Therapy and Multi-Target Strategies for CBS/PSP
Summary
Synergistic drug combinations, multi-target strategies, and sequential therapy protocols for corticobasal syndrome and progressive supranuclear palsy
Knowledge Graph
Related Hypotheses (30)
Bacterial Enzyme-Mediated Dopamine Precursor Synthesis
Score: 0.36
Purinergic Signaling Polarization Control
Score: 0.55
Mechanosensitive Ion Channel Reprogramming
Score: 0.51
TREM2-mediated microglial tau clearance enhancement
Score: 0.49
Lipid Droplet Dynamics as Phenotype Switches
Score: 0.46
Hippocampal CA3-CA1 circuit rescue via neurogenesis and syna
Score: 0.68
Vagal Afferent Microbial Signal Modulation
Score: 0.52
TREM2 Conformational Stabilizers for Synaptic Discrimination
Score: 0.41
Vocal Cord Neuroplasticity Stimulation
Score: 0.50
Hippocampal CA3-CA1 synaptic rescue via DHHC2-mediated PSD95
Score: 0.69
TREM2-Dependent Astrocyte-Microglia Cross-talk in Neurodegen
Score: 0.64
TREM2-Mediated Astrocyte-Microglia Cross-Talk in Neurodegene
Score: 0.61
Multiplexed Base Editing for Simultaneous Neuroprotective Ge
Score: 0.53
TREM2-Dependent Microglial Senescence Transition
Score: 0.69
Gamma entrainment therapy to restore hippocampal-cortical sy
Score: 0.68
Selective Acid Sphingomyelinase Modulation Therapy
Score: 0.65
CYP46A1 Overexpression Gene Therapy
Score: 0.63
Multi-Modal Stress Response Harmonization
Score: 0.60
TREM2-CSF1R Cross-Talk in Microglial Metabolic Reprogramming
Score: 0.59
PARP1 Inhibition Therapy
Score: 0.58
Senescent Microglia Resolution via Maresins-Senolytics Combi
Score: 0.55
Circadian Glymphatic Rescue Therapy (Melatonin-focused)
Score: 0.55
Targeted APOE4-to-APOE3 Base Editing Therapy
Score: 0.53
Cell-Type Specific TREM2 Upregulation in DAM Microglia
Score: 0.52
Near-infrared light therapy stimulates COX4-dependent mitoch
Score: 0.51
Ganglioside Rebalancing Therapy
Score: 0.50
Lysosomal Calcium Channel Modulation Therapy
Score: 0.49
Orexin-Microglia Modulation Therapy
Score: 0.49
Purinergic P2Y12 Inverse Agonist Therapy
Score: 0.48
Complement C1q Mimetic Decoy Therapy
Score: 0.48
Show 25 more
Related Analyses (28)
4R-tau strain-specific spreading patterns in PSP vs CBD
neurodegeneration · archived
Do tau strains or regional cellular environments primarily d
neurodegeneration · failed
4R-tau strain-specific spreading patterns in PSP vs CBD
neurodegeneration · completed
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · archived
APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · archived
Autophagy-lysosome pathway convergence across neurodegenerat
neurodegeneration · archived
Digital biomarkers and AI-driven early detection of neurodeg
neurodegeneration · archived
Neuroinflammation resolution mechanisms and pro-resolving me
neurodegeneration · archived
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · archived
Protein aggregation cross-seeding across neurodegenerative d
neurodegeneration · archived
Lipid raft composition changes in synaptic neurodegeneration
neurodegeneration · completed
Sleep disruption as cause and consequence of neurodegenerati
neurodegeneration · archived
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived
Synaptic pruning by microglia in early AD
neurodegeneration · archived
Mitochondrial transfer between astrocytes and neurons
neurodegeneration · archived
Epigenetic clocks and biological aging in neurodegeneration
neurodegeneration · archived
Circuit-level neural dynamics in neurodegeneration
neuroscience · archived
Gene expression changes in aging mouse brain predicting neur
neurodegeneration · archived
CRISPR-based therapeutic approaches for neurodegenerative di
neurodegeneration · archived
Tau propagation mechanisms and therapeutic interception poin
neurodegeneration · archived
SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas
neurodegeneration · completed
Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · archived
Senolytic therapy for age-related neurodegeneration
neurodegeneration · archived
Senescent cell clearance as neurodegeneration therapy
neurodegeneration · archived
TREM2 Therapeutic Strategy Post-INVOKE-2
neurodegeneration · completed
GBA-Synuclein Loop Therapeutics for PD
neurodegeneration · completed
Selective vulnerability of entorhinal cortex layer II neuron
neurodegeneration · archived
Show 23 more
Related Experiments (16)
4R-Tau Targeting Therapies for PSP and CBS
clinical · proposed · Score: 0.40
Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri
clinical · proposed · Score: 0.40
Brainstem Circuit Modulation for PSP
clinical · proposed · Score: 0.40
CBS vs PSP Phenotype Determinants — Single-Nucleus Multi-Omi
validation · proposed · Score: 0.40
ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
clinical · proposed · Score: 0.40
Levodopa Response Determinants in PSP — Biomarker-Guided Pre
clinical · proposed · Score: 0.40
N-of-1 Clinical Trial Design for CBS/PSP
clinical · proposed · Score: 0.40
PSP and CBS Biomarker Validation Study
clinical · proposed · Score: 0.40
Tau Pathology Initiation Zone Identification
clinical · proposed · Score: 0.40
Tau Spreading Network Mapping via Spatial Transcriptomics in
clinical · proposed · Score: 0.40
Microglial TREM2 Agonist In Vivo Efficacy
validation · proposed · Score: 0.40
TREM2 Agonist Therapy for Parkinson's Disease — Experimental
validation · proposed · Score: 0.40
TREM2 Function in Alzheimer's Disease — From Risk Variant to
validation · proposed · Score: 0.40
Alpha-Synuclein Aggregation Triggers — Sporadic PD Initiatio
clinical · proposed · Score: 0.40
tACS Connectivity Trial in Early Alzheimer's
clinical · proposed · Score: 0.40
Microbiome-Gut Barrier Signatures in ALS — Experiment Design
clinical · proposed · Score: 0.40
Show 11 more
See Also (15)
Transdiagnostic Proteomic Changes in Neurodegeneration
mechanism · Pages share 5 hypotheses
Transdiagnostic Proteomic Changes in Neurodegeneration
mechanism · Pages share 5 hypotheses
Therapeutic Targets in Neurodegeneration
mechanism · Pages share 5 hypotheses
Tau Seeding and Propagation Pathway
mechanism · Pages share 5 hypotheses
Systemic Infection and Tau Pathology Acceleration
mechanism · Pages share 5 hypotheses
Sex Differences in Neurodegeneration
mechanism · Pages share 5 hypotheses
Senescent Cell Clearance in Neurodegeneration
mechanism · Pages share 5 hypotheses
Retinal Degeneration Pathway in Neurodegeneration
mechanism · Pages share 5 hypotheses
Neuroinflammation in Parkinson's Disease Dementia and D
mechanism · Pages share 5 hypotheses
Microglial Priming Pathway in Neurodegeneration
mechanism · Pages share 5 hypotheses
Lipid Metabolism Dysregulation in Neurodegeneration
mechanism · Pages share 5 hypotheses
IL-1 Signaling Pathway in Neurodegeneration
mechanism · Pages share 5 hypotheses
HMGB1 Signaling in Neurodegeneration
mechanism · Pages share 5 hypotheses
gp130/IL-6 Family Cytokine Signaling in Neurodegenerati
mechanism · Pages share 5 hypotheses
Geniposide for Alzheimer's disease - immune biomarker t
mechanism · Pages share 5 hypotheses
Show 10 more